SPOTLIGHT: Does the patent cliff drive innovation?


Is generic competition good for the biotech and pharma industries? An article from The San Francisco Chronicle argues that as aging drugs go off patent, companies are forced to push innovation to new heights in an effort to render older drugs obsolete. Article

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.